Transarterial Radioembolization (TARE)/ Selective Internal Radiation Therapy (SIRT) for the Treatment of Malignant Cancers of the Liver – Commercial and Individual Exchange Medical Policyopen_in_new

UnitedHealthcare covers yttrium‑90 TARE/SIRT for individuals ≥19 with ECOG 0–2 for liver‑dominant HCC in non‑surgical candidates or as a bridge to transplant, unresectable intrahepatic cholangiocarcinoma, chemotherapy‑refractory predominant hepatic colorectal metastases, symptomatic neuroendocrine liver metastases after failed systemic therapy, and liver‑confined uveal melanoma (individuals <19 are covered without further review); all other indications are unproven and not medically necessary. Coverage requires documented ECOG 0–2, contrast liver imaging and relevant labs (including bilirubin), technetium‑99m MAA mapping with acceptable lung shunt and no clinically unacceptable nontarget deposition, documentation of prior therapies/chemo‑resistance where applicable, multidisciplinary team evaluation, absence/justification of absolute contraindications (e.g., unacceptable lung shunt, inability to catheterize hepatic artery, fulminant liver failure, pregnancy/lactation, severe coagulopathy or high tumor liver burden), and procedure/dosimetry documentation performed by appropriately trained providers.